Alexandre Evrard

2.7k total citations
80 papers, 1.9k citations indexed

About

Alexandre Evrard is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Alexandre Evrard has authored 80 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 33 papers in Molecular Biology and 15 papers in Cancer Research. Recurrent topics in Alexandre Evrard's work include Colorectal Cancer Treatments and Studies (14 papers), Pharmacogenetics and Drug Metabolism (10 papers) and Drug Transport and Resistance Mechanisms (10 papers). Alexandre Evrard is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Pharmacogenetics and Drug Metabolism (10 papers) and Drug Transport and Resistance Mechanisms (10 papers). Alexandre Evrard collaborates with scholars based in France, Australia and United States. Alexandre Evrard's co-authors include Pierre Cuq, Joseph Ciccolini, Laurence Vian, Isabelle Passagne, Jean‐Paul Brouillet, Philippe Depeille, Caroline Raynal, Serge Lumbroso, Cédric Mercier and Heribert Hirt and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and New Phytologist.

In The Last Decade

Alexandre Evrard

79 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexandre Evrard France 25 841 711 346 221 188 80 1.9k
Hiroyuki Kuroda Japan 28 1.2k 1.5× 507 0.7× 393 1.1× 139 0.6× 136 0.7× 151 2.8k
Axel Sauerbrey Germany 25 1.3k 1.5× 1.1k 1.5× 115 0.3× 260 1.2× 179 1.0× 72 2.6k
Radosław Zagożdżon Poland 25 792 0.9× 803 1.1× 102 0.3× 213 1.0× 61 0.3× 104 2.2k
Mark Steven Miller United States 25 1.1k 1.3× 510 0.7× 117 0.3× 604 2.7× 158 0.8× 97 2.2k
Ross Davey Australia 21 802 1.0× 730 1.0× 117 0.3× 221 1.0× 79 0.4× 43 1.7k
Peta E. Jackson United States 14 822 1.0× 683 1.0× 119 0.3× 383 1.7× 83 0.4× 17 1.8k
Gwo‐Tarng Sheu Taiwan 29 1.2k 1.4× 520 0.7× 163 0.5× 352 1.6× 53 0.3× 73 2.2k
Markus Schirmer Germany 22 467 0.6× 438 0.6× 118 0.3× 171 0.8× 90 0.5× 70 1.6k
Osamu Koiwai Japan 31 1.9k 2.3× 496 0.7× 145 0.4× 311 1.4× 143 0.8× 96 3.1k
Satoshi Toyoshima Japan 32 1.1k 1.3× 412 0.6× 136 0.4× 208 0.9× 65 0.3× 163 2.9k

Countries citing papers authored by Alexandre Evrard

Since Specialization
Citations

This map shows the geographic impact of Alexandre Evrard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandre Evrard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandre Evrard more than expected).

Fields of papers citing papers by Alexandre Evrard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandre Evrard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandre Evrard. The network helps show where Alexandre Evrard may publish in the future.

Co-authorship network of co-authors of Alexandre Evrard

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandre Evrard. A scholar is included among the top collaborators of Alexandre Evrard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandre Evrard. Alexandre Evrard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Adenis, Antoine, François Ghiringhelli, Thibault Mazard, et al.. (2024). Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. Cancer Chemotherapy and Pharmacology. 94(3). 443–452. 1 indexed citations
2.
Leenhardt, Fanny, Frédéric Fiteni, Séverine Guiu, et al.. (2022). Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects. Pharmaceutics. 14(4). 841–841. 9 indexed citations
3.
Barbolosi, Dominique, et al.. (2021). Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. Cancer Chemotherapy and Pharmacology. 88(2). 247–258. 2 indexed citations
4.
Leenhardt, Fanny, Séverine Guiu, Stéphane Pouderoux, et al.. (2021). Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug–drug interactions with oral targeted therapy. Cancer Chemotherapy and Pharmacology. 88(4). 723–729. 5 indexed citations
5.
Roger, Claire, Grégory Marin, Nicolas Molinari, et al.. (2020). Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. Antibiotics. 9(11). 793–793. 7 indexed citations
6.
Blay, Jean‐Yves, Alexandre Evrard, Marie Karanian, et al.. (2019). Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report. Journal of Medical Case Reports. 13(1). 245–245. 38 indexed citations
7.
Robert, Jacques, Marc Ychou, Jean-Christophe Boyer, et al.. (2016). Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients. Clinical Pharmacokinetics. 55(9). 1145–1157. 20 indexed citations
8.
Breuker, Cyril, Chris Planque, Jean‐Charles Nault, et al.. (2014). Characterization of a novel PXR isoform with potential dominant-negative properties. Journal of Hepatology. 61(3). 609–616. 16 indexed citations
9.
Bermont, Laurent, et al.. (2012). Lexical fields of predictive and personalized medicine. Annales de biologie clinique. 70(6). 651–658. 3 indexed citations
10.
Mouzat, Kévin, Éric Mercier, Anne Polge, et al.. (2011). A common polymorphism in NR1H2 (LXRbeta) is associated with preeclampsia. BMC Medical Genetics. 12(1). 145–145. 23 indexed citations
11.
Raynal, Caroline, Jean‐Marc Pascussi, Cyril Breuker, et al.. (2010). Pregnane × Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Molecular Cancer. 9(1). 46–46. 85 indexed citations
12.
Lallemant, Benjamin, Alexandre Evrard, Guillaume Chambon, et al.. (2010). Gene expression profiling in head and neck squamous cell carcinoma: Clinical perspectives. Head & Neck. 32(12). 1712–1719. 24 indexed citations
13.
Evrard, Alexandre, et al.. (2009). FORCA, a promoter element that responds to crosstalk between defense and light signaling. BMC Plant Biology. 9(1). 2–2. 24 indexed citations
14.
Tosi, Paola, et al.. (2007). Promoter analysis and immunolocalisation show that puroindoline genes are exclusively expressed in starchy endosperm cells of wheat grain. Plant Molecular Biology. 64(1-2). 125–136. 50 indexed citations
15.
Evrard, Alexandre, Donaldo Meynard, Emmanuel Guiderdoni, Philippe Joudrier, & Marie‐Françoise Gautier. (2006). The promoter of the wheat puroindoline-a gene (PinA) exhibits a more complex pattern of activity than that of the PinB gene and is induced by wounding and pathogen attack in rice. Planta. 225(2). 287–300. 17 indexed citations
16.
Fanciullino, Raphaëlle, Alexandre Evrard, Pierre Cuq, et al.. (2006). Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study. Anti-Cancer Drugs. 17(4). 463–470. 11 indexed citations
17.
Winum, Jean‐Yves, et al.. (2003). Synthesis and biological evaluation of Fotemustine analogues on human melanoma cell lines. European Journal of Medicinal Chemistry. 38(3). 319–324. 20 indexed citations
18.
Passagne, Isabelle, Alexandre Evrard, Jean‐Yves Winum, et al.. (2003). Cytotoxicity, DNA Damage, and Apoptosis Induced by New Fotemustine Analogs on Human Melanoma Cells in Relation to O6-Methylguanine DNA-Methyltransferase Expression. Journal of Pharmacology and Experimental Therapeutics. 307(2). 816–823. 26 indexed citations
19.
Vantyghem, Marie‐Christine, Christine Hober, Alexandre Evrard, et al.. (1999). Transient pseudo-hypoaldosteronism following resection of the ileum: Normal level of lymphocytic aldosterone receptors outside the acute phase. Journal of Endocrinological Investigation. 22(2). 122–127. 14 indexed citations
20.
Evrard, Alexandre, Laurence Vian, C. Aubert, & J. P. Cano. (1996). An in vitro nucleoside analog screening method for cancer gene therapy. Cell Biology and Toxicology. 12(4-6). 345–350. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroyuki Kuroda Breakdown of academic impact, for papers by Axel Sauerbrey Breakdown of academic impact, for papers by Radosław Zagożdżon Breakdown of academic impact, for papers by Mark Steven Miller Breakdown of academic impact, for papers by Ross Davey Breakdown of academic impact, for papers by Peta E. Jackson Breakdown of academic impact, for papers by Gwo‐Tarng Sheu Breakdown of academic impact, for papers by Markus Schirmer Breakdown of academic impact, for papers by Osamu Koiwai Breakdown of academic impact, for papers by Satoshi Toyoshima
Rankless by CCL
2026